Lilly and Ascidian strike up to $1.9B RNA-editing pact for kidney disease
Eli Lilly and Ascidian Therapeutics unveiled a collaboration/licensing agreement potentially worth up to $1.9 billion to develop RNA-editing therapies for kidney diseases, following early data suggesting the approach may be safe in humans.